

AMENDMENTS TO THE CLAIMS

1. (Canceled)
2. (Currently amended) An isolated tumor antigen peptide that is a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide comprises ~~an~~the amino acid sequence of ~~any one of~~ SEQ ID ~~NOS~~NO: 3 to 52 and binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.
3. (Original) The tumor antigen peptide of claim 2 wherein the HLA antigen is HLA-A24 or HLA-A2.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)

11. (Currently amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides and the derivatives according to any one of claims 2, 5-7 and 9claim 2, 3 or 16, and a pharmaceutically acceptable carrier.

12. (Currently amended) A recombinant polypeptide produced by expressing a recombinant DNA comprising at least one of polynucleotide that encodes the tumor antigen peptide or derivative according to any one of claims 2, 3, 5-7 and 9claim 2, 3 or 16.

13. (Previously Presented) A pharmaceutical composition for treating a tumor, which comprises as an active ingredient the recombinant polypeptide of claim 12, in an amount effective for treating said tumor and a pharmaceutically acceptable carrier.

14. (Currently amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or the derivative according to any one of claims 2, 3, 5-7 and 9claim 2, 3 or 16.

15. (Original) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 12.

16. (NEW) The isolated tumor antigen peptide according to claim 2 consisting of the amino acid sequence of SEQ ID NO:3.

17. (NEW) An isolated tumor antigen peptide that is a partial peptide having at least 14 amino acids of a protein consisting of the amino acid sequence of SEQ ID NO:2.

18. (NEW) An isolated tumor antigen peptide that is a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 3 or a variant of SEQ ID NO: 3 having one or more amino acid substitutions retaining a HLA-A24 binding motif and binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.